Reported 29 days ago
Analysts predict that Novo Nordisk will rebound and potentially outperform Eli Lilly in the market for obesity drugs, following a dip in shares for Novo. Despite a significant decline of 25% since June, forecasts indicate that Novo's stock could increase by 25% over the next year, compared to 13% for Lilly. As both companies prepare to report earnings soon, investors are focused on production capabilities and upcoming data from Novo's new weight-loss drug trials, which may further influence market dynamics.
Source: YAHOO